Leerink analyst Ana Gupte lowered her price target for Molina Healthcare to $75 from $105 after the EPS miss in Q1 and guide-down. Rapid growth in membership has posed short-term operational challenges for the company, but the medium-term growth story is "very much intact," the analyst tells investors in a research note. Gupte sees the sell-off on Friday as a buying opportunity, with the turnaround likely to be swift and the long-term story of growth in Managed Medicaid remaining "strong." The analyst reiterates an Outperform rating on the shares.